DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Epirubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab in Treating Women With HER2-Positive Stage III or Stage IV Breast Cancer

Information source: National Cancer Institute (NCI)
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Breast Cancer

Intervention: trastuzumab (Biological); cyclophosphamide (Drug); docetaxel (Drug); epirubicin hydrochloride (Drug); conventional surgery (Procedure); neoadjuvant therapy (Procedure)

Phase: Phase 2

Status: Completed

Sponsored by: Teikyo University

Official(s) and/or principal investigator(s):
Tadashi Ikeda, MD, Study Chair, Affiliation: Teikyo University

Summary

RATIONALE: Drugs used in chemotherapy, such as epirubicin, cyclophosphamide, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving chemotherapy and a monoclonal antibody before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase II trial is studying how well giving epirubicin and cyclophosphamide followed by docetaxel and trastuzumab works in treating women with HER2-positive stage IIIB, stage IIIC, or stage IV primary breast cancer.

Clinical Details

Official title: Neoadjuvant Epirubicin/Cyclophosphamide Followed by Docetaxel Combined With Trastuzumab for the Patients With HER-Positive Advanced Breast Cancer

Study design: Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Pathological complete response

Secondary outcome:

Clinical response

Recurrence-free survival

Overall survival

Adverse event

Detailed description: OBJECTIVES: Primary

- Determine the pathological complete response in women with HER2-positive stage IIIB-IV

breast cancer treated with neoadjuvant epirubicin hydrochloride and cyclophosphamide followed by docetaxel and trastuzumab (Herceptin®). Secondary

- Determine the clinical response in patients treated with this regimen.

- Determine the recurrence-free survival of patients treated with this regimen.

- Determine the overall survival of patients treated with this regimen.

OUTLINE: This is a multicenter study. Patients receive epirubicin hydrochloride and cyclophosphamide in weeks 1-3. Treatment with epirubicin hydrochloride and cyclophosphamide repeats every 3 weeks for 4 courses. Patients then receive docetaxel in week 13 and trastuzumab (Herceptin®) in weeks 13-15. Treatment with docetaxel and trastuzumab repeats every 3 weeks for 4 courses. Patients then undergo appropriate surgery. After surgery, patients with hormone receptor-positive disease receive trastuzumab once weekly and either tamoxifen with or without a luteinizing hormone-releasing hormone agonist or an aromatase inhibitor. Treatment continues for 40 weeks. PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.

Eligibility

Minimum age: 20 Years. Maximum age: 65 Years. Gender(s): Female.

Criteria:

DISEASE CHARACTERISTICS:

- Diagnosis of primary breast cancer

- Stage IIIB, IIIC, or IV disease

- No inflammatory disease

- HER2 over-expressing tumor as assessed by immunohistochemistry and/or fluorescent in

situ hybridization

- Hormone receptor status known

PATIENT CHARACTERISTICS:

- Female

- Menopausal status not specified

- Performance status 0-1

- WBC ≤ 10,000/mm³

- Absolute neutrophil count ≥ 2,000/mm³

- Platelet count ≥ 100,000/mm³

- Hemoglobin ≥ 9. 5 g/dL

- SGOT/SGPT ≤ 60 IU/L

- Bilirubin ≤ 1. 5 mg/dL

- Creatinine ≤ 1. 5 mg/dL

- LVEF ≥ 55%

- No signs of pneumonitis

PRIOR CONCURRENT THERAPY:

- No prior surgery except for biopsy

- No prior or concurrent chemotherapy and/or hormonal therapy

- No prior or concurrent biological therapy

- No prior or concurrent radiotherapy except postoperative radiotherapy

Locations and Contacts

Niigata Cancer Center Hospital, Niigata 951-8566, Japan

Keio University Hospital, Tokyo 160-8582, Japan

Teikyo University School of Medicine, Tokyo 173-8605, Japan

Shikoku Cancer Center, Matsuyama-shi, Ehime 791-0288, Japan

National Kyushu Cancer Center, Fukuoka-shi, Fukuoka 811-1395, Japan

Additional Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Starting date: January 2006
Last updated: December 17, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017